ATLAS was the T cell antigen discovery platform behind both the herpes and cancer vaccine programs. It profiled patient immune responses to rank the antigens most visible to T cells.
The platform differentiated Genocea by grounding candidate design in measured human immune data. It remained the core technical asset after the 2017 pivot to neoantigen vaccines.
GEN-003 was the immunotherapy candidate for genital herpes that met its primary endpoint in a Phase 2 trial. The study showed a 58 percent reduction in viral shedding rates versus baseline.
After the 2017 pivot to cancer vaccines, the company sought external options for GEN-003 rather than funding it internally. The candidate did not advance further before the 2022 shutdown.
GEN-009 was the lead neoantigen cancer vaccine advanced after the 2017 strategic shift to immuno-oncology. The candidate used ATLAS to select patient specific neoantigens for individualized immunotherapy.
Development prioritized GEN-009 while GEN-003 was positioned for partnering or strategic alternatives. The program ended when Genocea wound down operations in May 2022.
